Standard BioTools Inc
LAB - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$239.47M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $239.47 Million |
|---|---|
| Enterprise Value | $9.55 Million |
| Earnings per Share | $-0.2 |
| Beta | 1.35 |
| Outstanding Shares | 390,881,000 |
Return
| Return on Equity | 15.72% |
|---|---|
| Return on Assets | 13.54% |
| Return on Invested Capital | -16.49% |
Valuation & Multiples
| P/E Ratio | -2.65 |
|---|---|
| PEG | 13.21 |
| Price to Sales | - |
| Price to Book Ratio | 0.62 |
| Enterprise Value to Revenue | 0.15 |
| Enterprise Value to EBIT | -0.1 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 4.2 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 3, 2026
EPS Estimate
$-0.02
Consensus analyst estimateRevenue Estimate
$18.80 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
$-0.02
Consensus analyst estimateRevenue Estimate
$21.00 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 256.16% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.64%▼ 74.56% |
|---|---|
| Total Invested | $4.76M▼ 98.06% |
| Investors Holding | 6▼ 143.00% |
About Standard BioTools Inc
627 employees
CEO: Stephen Linthwaite
Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-om...